Solix Biofuels has announced that they have received more than $16 million from inside investors in the first part of its Series B round of financing. The monies will be used to drive the commercialization of the company’s algae growth system, the AGS, that utilizes Solix’s proprietary high-productivity photobioreactors. Investors include Bohemian Ventures, The Southern Ute Alternative Energy Fund and I2BF Global Ventures.

In tandem with the infusion of funds, Solix is changing its name to Solix BioSystems. The company says this name change better reflects its role as a leading provider of algae production systems.

“This new round of financing from current investors demonstrates their continued excitement and support for our progress,” said Joel Butler, Solix’s Chief Executive Officer. “Solix is poised to launch its first commercial AGS product into the market. With our focus on providing customers with algae production systems, Solix BioSystems better reflects the Company’s objectives.”